Consensus Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 19:55:00 13/02/2026 +03			5-day change	1st Jan Change
154.70 ^EUR	+4.81%		+13.67%	+30.00%

02-13	Genfit to Receive $20 Million Milestone Payment Linked to Sales of Ipsen's Iqirvo	MT
02-13	Ipsen Remains in the Green with UBS Support

Evolution of the Average Target: Ipsen

Evolution of the Target Price: Ipsen

Changes in Analyst Recommendations: Ipsen

ee1a.A855EXD_tqzx7uOcSWn2s89v0p4LZcf4RRR5H4wUr-Y.YoY-KCmq4tiktIntEzOT3psFmOxJIoafLDlAJ8pV9aJWtx8kOZHk3pqF0w~fc07eec3dbfbf19962033e6c44d1b000

Analysts' recommendations: Ipsen

02-13	Ipsen Remains in the Green with UBS Support
02-12	Ipsen: Markets applaud strong finish to 2025 and better-than-expected 2026 outlook
01-14	Ipsen, Top Gainer on the SBF 120 and SRD at Wednesday, January 14, 2026 Close
01-14	Ipsen and EMS-Chemie Shine on the Stock Market, Vistry and Pearson Struggle
01-08	UBS No Longer Recommends Buying Ipsen, Citing Full Valuation
11-26	BNP Paribas Downgrades Ipsen to Underperform, Trims PT	MT
11-18	AlphaValue/Baader Europe Ups Ipsen's EPS Forecasts After Q3 Beat, 'Substantial' FY25 Outlook Upgrade	MT
11-17	Ipsen raises 2025 outlook after stronger Somatuline
11-07	Ipsen to Present Positive Data on PBC at AASLD 2025
22/10/25	Ipsen: Robust Q3 fuels a guidance upgrade
13/10/25	Ipsen: UBS reiterates buy recommendation
12/09/25	Sadif Investment Analytics Upgrades Ipsen to Hold	MT
13/08/25	RBC Keeps Ipsen at Outperform Amid Upcoming Potential Catalysts	MT
12/08/25	Ipsen: RBC still a buyer, TP EUR148
31/07/25	Ipsen: Performance across key offerings fell short of expectations, unsettling investors
04/06/25	Deutsche Bank Restarts Ipsen Coverage with Buy Rating	MT
04/06/25	Ipsen: Deutsche Bank resumes coverage as a buyer
06/05/25	RBC Lifts Ipsen Price Target on Iqirvo Q1 Growth, New Indication Opportunity	MT
06/05/25	Ipsen: RBC raises target price
17/04/25	AlphaValue/Baader Europe Keeps Buy Rating on Ipsen After Q1 Results	MT
16/04/25	Ipsen: In-line Q1; 2025 guidance unchanged
02/04/25	Ipsen: Deutsche Bank upgrades to buy
28/03/25	Ipsen: Ipsen remains a compelling Smaller Pharma investment
13/02/25	Ipsen: Q4 beat led by Somatuline
11/02/25	Ipsen: Oddo BHF raises its target price on the stock